Kura Oncology, Inc. (KURA)
12.40
+0.51
(+4.29%)
USD |
NASDAQ |
Aug 24, 16:00
13.12
+0.72
(+5.81%)
After-Hours: 20:00
Kura Oncology Gross Profit Margin (Quarterly) : 97.07% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.07% |
| March 31, 2026 | 96.62% |
| December 31, 2025 | 97.35% |
| September 30, 2025 | 99.21% |
| Date | Value |
|---|---|
| June 30, 2025 | 98.53% |
| March 31, 2025 | 98.29% |
| December 31, 2024 | 99.62% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -- |
| Fortress Biotech, Inc. | 61.50% |
| Syndax Pharmaceuticals, Inc. | 95.59% |
| Spero Therapeutics, Inc. | -- |
| Gossamer Bio, Inc. | 97.27% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -168.9% |
| Return on Assets | -44.82% |
| Return on Invested Capital | -150.4% |
| Profit Margin (Quarterly) | -327.3% |
| Operating Margin (Quarterly) | -349.8% |
| Return on Net Operating Assets | -1.45K% |